At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KLRA Kailera Therapeutics
Trading 07-10 10:36:08 EDT
20.70
-0.31
-1.48%
High22.05Low20.69Vol73.44K
Open21.00D1 Closing21.01Amplitude6.47%
Mkt Cap2.68BTradable Cap929.88MTotal Shares129.54M
T/O1.54MT/O Rate0.16%Tradable Shares44.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Kailera Therapeutics Files Form 3 for Chief Corporate Affairs Officer Kathleen Tregoning
Reuters  ·  07-09 04:16
Kailera Therapeutics Files Form 3 for Chief Corporate Affairs Officer Kathleen Tregoning
Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  07-08 21:35
Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  07-08 01:30
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)
Race to Launch Weight-loss Pills Heats up as Smaller Players Advance
Reuters  ·  07-08 00:12
Race to Launch Weight-loss Pills Heats up as Smaller Players Advance
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  07-07 22:40
Wall Street Analysts Are Bullish on Top Healthcare Picks
Kailera Therapeutics announces positive Phase 3 data for weight loss drug
TIPRANKS  ·  07-07
Kailera Therapeutics announces positive Phase 3 data for weight loss drug
Shares of Kailera Therapeutics up 1.9% Premarket After Weight-loss Drug Meets Main Goal of Late-stage Trials in China
THOMSON REUTERS  ·  07-07
Shares of Kailera Therapeutics up 1.9% Premarket After Weight-loss Drug Meets Main Goal of Late-stage Trials in China
Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success
Reuters  ·  07-07
Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success
Kailera's GLP-1 Drug Meets Main Goal of Late-stage Trials
Reuters  ·  07-07
Kailera's GLP-1 Drug Meets Main Goal of Late-stage Trials
Kailera Reports Phase 3 China Data Showing up to 10.9% Weight Loss with Oral GLP-1 Drug Kai-7535
Reuters  ·  07-07
Kailera Reports Phase 3 China Data Showing up to 10.9% Weight Loss with Oral GLP-1 Drug Kai-7535
Kailera Therapeutics - Hrs-7535 Lowers Hba1c by 1.5%-1.68% in Phase 3 Type 2 Diabetes Trial
THOMSON REUTERS  ·  07-07
Kailera Therapeutics - Hrs-7535 Lowers Hba1c by 1.5%-1.68% in Phase 3 Type 2 Diabetes Trial
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule Glp-1 Receptor Agonist Hrs-7535/kai-7535
THOMSON REUTERS  ·  07-07
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule Glp-1 Receptor Agonist Hrs-7535/kai-7535
Kailera Therapeutics Inc: Advancing Kai-7535 in a Global Phase 2 Clinical Trial in People Living with Obesity or Overweight
THOMSON REUTERS  ·  07-07
Kailera Therapeutics Inc: Advancing Kai-7535 in a Global Phase 2 Clinical Trial in People Living with Obesity or Overweight
Kailera Therapeutics Inc: Kai-7535 Trial Initiated in April 2026, with Data Expected in 2027
THOMSON REUTERS  ·  07-07
Kailera Therapeutics Inc: Kai-7535 Trial Initiated in April 2026, with Data Expected in 2027
Kailera Therapeutics - no Liver Safety Signals Observed in Phase 3 Trials of Hrs-7535
THOMSON REUTERS  ·  07-07
Kailera Therapeutics - no Liver Safety Signals Observed in Phase 3 Trials of Hrs-7535
Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Dow Jones  ·  06-29
Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks
THOMSON REUTERS  ·  06-06
Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
GlobeNewswire  ·  06-06
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
GlobeNewswire  ·  05-29
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  05-28
Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)

Introduction

Company Name.
Kailera Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--